Autonomic Cardiovascular Responses in Acclimatized Lowlanders on Prolonged Stay at High Altitude: A Longitudinal Follow Up Study

Priyanka Dhar¹, Vijay K. Sharma¹, Kalpana B. Hota¹, Saroj K. Das¹, Sunil K. Hota¹, Ravi B. Srivastava¹, Shashi B. Singh²*

¹ Defence Institute of High Altitude Research, Defence Research & Development Organisation, C/o 56 APO, Leh-Ladakh, Jammu and Kashmir, India
² Defence Institute of Physiology and Allied Sciences, Defence Research & Development Organisation, Lucknow Road, Timarpur, Delhi, India

Abstract

Acute exposure to hypobaric hypoxia at high altitude is reported to cause sympathetic dominance that may contribute to the pathophysiology of high altitude illnesses. The effect of prolonged stay at high altitude on autonomic functions, however, remains to be explored. Thus, the present study aimed at investigating the effect of high altitude on autonomic neural control of cardiovascular responses by monitoring heart rate variability (HRV) during chronic hypobaric hypoxia. Baseline electrocardiography (ECG) data was acquired from the volunteers at mean sea level (MSL) (<250 m) in Rajasthan. Following induction of the study population to high altitude (4500–4800 m) in Ladakh region, ECG data was acquired from the volunteers after 6 months (ALL 6) and 18 months of induction (ALL 18). Out of 159 volunteers who underwent complete investigation during acquisition of baseline data, we have only included the data of 104 volunteers who constantly stayed at high altitude for 18 months to complete the final follow up after 18 months. HRV parameters, physiological indices and biochemical changes in serum were investigated. Our results show sympathetic hyperactivation along with compromise in parasympathetic activity in ALL 6 and ALL 18 when compared to baseline data. Reduction of sympathetic activity and increased parasympathetic response was however observed in ALL 18 when compared to ALL 6. Our findings suggest that autonomic response is regulated by two distinct mechanisms in the ALL 6 and ALL 18. While the autonomic alterations in the ALL 6 group could be attributed to increased sympathetic activity resulting from increased plasma catecholamine concentration, the sympathetic activity in ALL 18 group is associated with increased concentration of serum coronary risk factors and elevated homocysteine. These findings have important clinical implications in assessment of susceptibility to cardio-vascular risks in acclimatized lowlanders staying for prolonged duration at high altitude.

Introduction

The autonomic nervous system (ANS) plays an important role in the regulation of a number of physiological processes during normal and pathophysiological conditions. Alteration in the ANS responses has been associated with the progression of cardiovascular diseases [1]. The ANS is influenced by both extrinsic factors like environment, stress etc as well as intrinsic factors that include hormonal changes [2]. Alteration in autonomic response is generally manifested through alterations in heart rate variability (HRV) [3,4]. Several investigators have used HRV analysis to assess autonomic functions in field study set ups owing to its advantages like portability, non-invasiveness, faster data acquisition, cost-effectiveness and reliability [5–8]. Environmental stress like acute exposure to hypoxia at high altitude is reported to diminish linear HRV and increased nonlinear HRV thereby resulting in alterations in autonomic functions of the nervous system [9]. Though there is reduction in both high and low frequency band power at high altitude, the low to high frequency power ratio increases [10–12].

The effect of rapid ascent to high altitude on autonomic cardiovascular modulation and its relationship with spectral components of HRV during AMS has been previously documented [13,14]. Studies by Bernardi et al. (2007) have shown exaggerated sympathetic activation in subjects with AMS while sympathetic activation was reduced in Himalayan high altitude natives [15]. Even after long-term acclimatization at sea level, high-altitude natives showed lower sympathetic activation, indicating a persisting high altitude adaptation [16]. Comparative evaluation of the influence of autonomic nervous system on heart and peripheral circulation in native high-altitude residents and sea-level residents at high altitude showed that even after acclimatization for one week, lowlanders showed sympathetic activation and skin vasoconstriction, while native highlanders residents did not show reduced vagal tone when compared to sea-level residents [17]. Intermittent exposure to hypoxia in athletes unacclimatized to high altitude on the other hand resulted in
increased LF/HF ratio which is a determinant of sympatho-vagal balance and signifies sympathetic over-activity [18]. Previous studies have also demonstrated sympathetic dominance in resting subjects staying for a period of one month at extreme altitude of 5050 m [19]. Power spectral analysis showed reduced HRV with a virtual increase in the low frequency (LF) component during exposure to high altitude [16,20], signifying an increased sympathetic modulation of the sinus node in response to hypobaric hypoxia. Over activation of the sympathetic neural system has been reported in non-natives following exposure to hypobaric hypoxia at high altitude [21]. In addition, there are other studies that have shown persistent increase in sympathetic nerve activity and chemosensitivity even after short duration of exposure to normobaric hypoxia [22,23]. A recent study by Prabhakaran and Tripathi (2011) showed autonomic modulation on acute exposure to hyperoxic hypobaria in simulated altitude of 4574 m [24]. However, most of these studies were performed to evaluate the consequence of acute and intermittent hypoxia on the autonomic nervous system and the effect of prolonged stay at high altitude on cardiovascular autonomic system remains ambiguous.

According to the report of World Health Organization (WHO), approximately 33 million people travel to altitudes above 3000 m each year [25]. A large number of lowlander population stay for long durations at high altitude due to occupational requirements and call of duty. Despite considerable research on the adverse effects of high altitude on human health, information on effect of prolonged stay at high altitude on the physiological functions of lowlanders is relatively sparse. The present study therefore aimed at investigating the differential temporal regulation of autonomic responses in acclimatized lowlanders (sea level populations staying at high altitude after acclamalization) on prolonged stay at high altitude. The alterations in autonomic response in acclimatized lowlanders on different durations of stay at high altitude were evaluated through longitudinal follow up on a relatively large cohort. With an objective to determine the metabolic correlates for the sympatho-vagal response at high altitude, we estimated serum concentration of coronary risk factors including cholesterol, triglycerides, high density lipoprotein (HDL), low density lipoprotein (LDL) and very low density lipoprotein (VLDL). The possible influence of secondary hypertension due to kidney malfunction that could influence the autonomic response was also investigated by estimating creatinine and blood urea nitrogen [26]. Liver function tests comprising of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) as well as serum folic acid, vitamin B12 and homocysteine levels were also estimated [27–30]. Concentration of serum angiotensin converting enzyme (ACE) and angiotensin II (Ang II) and plasma catecholamines norepinephrine and epinephrine was also determined [31,32].

Materials and Methods

Ethical clearance

The experimental protocol was approved by the ethics committee on human investigation of Defence Institute of High Altitude Research (DIHAR), Defence Research and Development Organisation (DRDO), Leh-Ladakh, India in accordance to Indian Council of Medical Research (ICMR) guidelines, and informed written consent was obtained from all the volunteers prior to enrollment.

Study protocol and volunteers

The study was conducted in actual field conditions in Ladakh region, during August 2009-March 2012. Volunteers who had stayed for more than 24 months at sea level were enrolled at Lalgarh Jattan, Rajasthan (<250 m MSL) in May-July 2010. The volunteers were explained about the study purpose, protocol and expected outcomes and informed consent was obtained. Preliminary screening was performed based on eligibility criterion L1 comprising of age, gender, education, monthly income and physical and physiological ailments. A medical questionnaire comprising questions related to occurrence of chronic diseases, physical and physiological ailments, heart problems, stroke, epilepsy, head injury, drug abuse, psychological disorders and general health status was administered to all the volunteers. Volunteers were then screened for compliance to eligibility criteria L2 comprising of core behavioral measures (CBM) like core alcohol consumption (section A), core tobacco use (section C), core diet (section D) and core physical activity (section P) in accordance with WHO guidelines [33] and with Beck Depression Inventory (BDI) score [34] to investigate the presence of hitherto undetected depression (Table 1). The information was verified from a close acquaintance of the volunteer. Lake Louis Score for acute mountain sickness (AMS) was administered to the participants at high altitude to negate possible occurrence of AMS symptoms.

Out of 299 volunteers between age group 23–35 of Indo-European origin who enrolled for the study, 159 volunteers qualified both L1 and L2 criterion and underwent complete investigation during acquisition of baseline data at MSL (<250 m) in Rajathan region. Following induction of the study population to high altitude (4500–4800 m) in Ladakh region of India, only 118 volunteers could be followed up after 6 months (ALL 6) and finally 104 volunteers who constantly stayed at high altitude for 18 months qualified for the final follow up after 18 months (ALL 18), the remaining being drop outs or de-inductees (Fig. 1). In both phases, volunteers at high altitude were considered to be acclimatized when Lake Louise scores were <2 [35]. The physical activity was maintained at a constant level for all the volunteers throughout the duration of the study to negate the influence of physical activity of cardiac autonomic responses.

Physiological measurements

Systolic and diastolic blood pressure (SBP and DBP), pulse rate (PR) and hemoglobin oxygen saturation (SpO2) were obtained in sitting position after 5 minutes rest prior to the investigation. Height was measured using a portable anthropometer. Body weight was measured using a portable digital scale (Omron Digital Weight Scale HN-286, Omron Healthcare Co., Kyoto, Japan). Body mass index (BMI) was calculated and expressed as kg/m².

ECG data acquisition and analysis

For recordings on ECG and respiration rate, volunteers were made to relax in sitting position for 15 minutes for habituation to the instrument and test environment. Recordings were acquired using BioHarness Physiology Monitoring System (Zephyr BioHarness data acquisition system with 3-lead configuration, BIOPAC Systems, Inc., 42 Aero Camio, Goleta, CA, USA) with MP 150 hardware and AcqKnowledge 3.9.1030 software. Raw data was acquired for 10 min with 250 Hz sample rate and post acquisition data processing was performed using AcqKnowledge 4.0.0 software. Artifacts, cumulative RR periods, and extra systoles were manually processed by calculation of interpolated or extrapolated values. The HRV indices with power spectral analyses were calculated by HRV analysis software 1.1 from the surface electrocardiogram [36]. The time-domain parameters were mean HR, mean RR, RMSSD, NN50 and pNN50 were calculated directly from the raw RR interval time series. RR triangular index and TINN were calculated as geometric measures of HRV. SD1 was measured as the non-linear parameter of
short-term HRV from Poincaré plot. In frequency-domain analysis power spectral density (PSD) of RR series was calculated by nonparametric Fast Fourier Transform (FFT) method. The parameters for frequency-domain included powers of LF, HF and TP in absolute values, normalized power of LF and HF bands, and the LF to HF ratio.

Biochemical estimations

Serum and plasma were obtained from fasting blood samples collected from the volunteers in morning hours under aseptic conditions. Cholesterol, triglycerides, high density lipoprotein (HDL), low density lipoprotein (LDL), cholesterol/HDL, LDL/HDL and very low density lipoprotein (VLDL) were measured by CHOD-POD, GPO-POD and direct enzyme clearance methods [37–40] to assess coronary risk profile. Hemoglobin (Hb) was estimated by converting all forms of hemoglobin to colored cyanometemoglobin and measured by a colorimeter while hematocrit (Hct) was measured using hematocrit reader according to previously described protocol [41]. Homocysteine, folic acid and vitamin B12 were measured by chemiluminescence method [42–44]. Creatinine and blood urea nitrogen (BUN) were measured spectrophotometrically with Jaffe’s kinetics and Urease method respectively [45,46]. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured spectrophoto-

dmatically [47]. Serum angiotensin converting enzyme (ACE) concentration was estimated by Boster’s human ACE ELISA kit (Wuhan Boster Biological Technology Ltd., Wuhan, China). Serum angiotensin II concentration was estimated spectrophoto-

dmatically using RayBio® angiotensin II Enzyme Immunoassay (EIA) kit (Ray Biotech, Inc., Norcross, GA, USA). Plasma epinephrine and norepinephrine concentration were estimated

| Table 1. Baseline characteristics of volunteers included in the study. |
|---------------------------------------------------------------|
| **Level 1 (L1) Criteria**                                      |
| **Parameter** | **Criteria** |
| 1 Age and anthropometric measures | |
| Age (years) | 23–35 |
| Gender | Male |
| Education (years) | 12±2* |
| Monthly earnings (INR) | 18000±2500* |
| 2 Medical history/Health status | |
| Any serious health illnesses | NA |
| Head injury resulting in loss of consciousness | NA |
| Any form of seizures, delirium tremens or convulsions | NA |
| Heart attack or any heart problem | NA |
| Cancer | NA |
| Allergies to medications, foods, animals, chemicals, or other agent | NA |
| Lung diseases such as asthma, emphysema, or chronic bronchitis | NA |
| Surgeries or hospitalizations | NA |
| Hypertension | NA |
| Diabetes | NA |
| Viral Hepatitis | NA |
| Dementia/Memory Impairment | NA |
| Stroke/Infarction/Cerebral Hemorrhage | NA |
| Kidney Disease | NA |
| GERD symptoms | NA |
| Chest Pain | NA |
| Congenital Heart Disease | NA |
| Neurological Problem/Epilepsy | NA |
| Familial Disorders | NA |
| **Level 2 (L2) Criteria (Core Behavioral Measures)** | |
| **Parameter** | **Criteria** |
| 1 Alcoholism | Non-alcoholics |
| 2 Smoking of tobacco products | Non-smokers |
| 3 Diet | Vegetarian and non-vegetarian |
| 4 Physical activity | Mild to moderate |
| BDI Score | 4.85±3.96* |

*Plus-minus values are mean ± SD; NA indicates not applicable.
Statistical analysis

Data acquired from only those individuals who participated throughout the study was considered for statistical analysis. Mean ± SEM was calculated for each group. Statistical analysis was performed using ANOVA with Duncan’s Post Hoc test for comparisons between groups using SPSS 17.0 Statistics software (SPSS, Chicago, IL, USA). Relations between variables were analyzed by calculating the Pearson product-moment correlation coefficients. P-values < 0.05 (two tailed) were considered to be significant. All the raw data was archived in the laboratory and a copy of the same was submitted to central records keeping centre of DIHAR.

Results

Physiological measures

SBP and DBP values were within the normal physiological range during the baseline and follow ups. Pulse rate was significantly higher in ALL 6 and ALL 18 when compared to the baseline values. The SpO2 at ALL 6 and ALL 18 significantly reduced when compared with the baseline data. ALL 6 showed increased pulse rate and reduced SpO2 when compared to ALL 18. BMI remained within the normal physiological range during baseline and follow ups (Table 2).

Autonomic responses

ECG data analysis showed progressive shortening of overall HRV indicators viz. mean RR, SDNN, RRTI, TINN and TP in ALL 6 and ALL 18 when compared to the baseline study group. The indicators of sympathetic activity viz. mean HR and LF (nu) showed significantly higher values in ALL 6 and ALL 18 when compared with the baseline data. The parasympathetic activity predictors, such as RMSSD, NN50, pNN50, SD1, HF power and HF (nu) also significantly decreased in the ALL 6 and ALL 18 in comparison to the baseline values. The LF/HF ratio (sympathovagal balance) increased significantly in the ALL 6 and ALL 18 when compared with the baseline data. Respiration rate was also found to be increased significantly in the ALL 6 and ALL 18 in comparison with baseline. Sympathetic activity was maximum in ALL 6 along with lowest overall HRV and significant reduction in parasympathetic response when compared to baseline as well as ALL 18 (Table 3).

Biochemical and molecular changes in the serum

Hemoglobin and hematocrit increased significantly in ALL 6 and ALL 18 when compared with baseline values. ALL 18 showed highest hemoglobin and hematocrit concentration during the follow up study. BUN, creatinine, ALT and AST values remained within the normal reference range during the baseline and follow ups (Table 4).

Results of serum coronary risk factor profiling have been described in Table 5. Serum cholesterol, triglycerides, HDL, VLDL, vitamin B12 and folic acid concentration were within the...
normal reference range. However, serum LDL, cholesterol/HDL and LDL/HDL concentration increased significantly beyond the reference range in ALL 18 and was higher in comparison to baseline and ALL 6 values. Serum homocysteine concentration was also significantly higher than the reference range in ALL 6 and ALL 18 (Table 5, Fig. 2). Serum homocysteine concentration was significantly higher in the ALL 18 population in comparison to ALL 6.

No significant change was observed in serum ACE and angiotensin II concentration during the follow ups (Fig. 3). Plasma norepinephrine and epinephrine concentration increased significantly in the ALL 6 population in comparison with baseline and ALL 18 population (Fig. 4).

**Discussion**

The reduced partial pressure of oxygen on ascent to high altitude leads to decreased tissue oxygenation, an inimitable condition called hypobaric hypoxia, which culminates in a number of pathophysiological complications [48–52]. The function of ANS also gets adversely affected in hypobaric hypoxia at high altitude [12,16,17,53–56]. Though acute high altitude exposure is reported to cause alterations in the cardiovascular system [57–59], the physiological response to prolonged hypobaric hypoxia has been less studied. In the present longitudinal study, increased pulse rate and reduced SpO₂ was observed in the ALL 6 and ALL 18 groups in comparison with the baseline. Previous studies to determine the relationship between SpO₂ and arterial blood pressure in healthy humans have attributed the decrease in SpO₂ to increased blood pressure in persons with oxygen desaturation at high altitudes [60,61]. Studies by Naeiji et al. (2010) have also shown decreased RR intervals and increased systolic blood pressure in sea level natives even after 7 days of stay at an altitude of 4970 m [16]. Similar studies conducted by Kanai et al. 2001, on untrained sojourners also showed a decrease in LF and HF even at altitudes of 3700 m [12]. Malhotra et al. (1976), during their investigations on effect of stay at high altitude for more than one year on the autonomic responses noted preponderance of the sympathetic activity even at an altitude of 3500 m [84]. The effect of such longer duration of stay at extreme altitudes above 4500 m, however, remained to be investigated. A unique study by Farinelli et al. (1994), on the effect of postural change on the heart rate, LF and HF of acclimatized lowlanders staying at extreme altitudes of 5050 m for one month showed decreased maximal heart rate and reduced sensitivity of the heart to adrenergic drive [75]. However, the limited number of 5 human subjects warrants a similar study in larger populations. Determination of autonomic activity by measuring muscle nerve sympathetic activity (MNSA) on non natives during exposure to hypobaric hypoxia showed overactivity of the sympathetic neural system [21]. Persistent increase in sympathetic nerve activity and chemosensitivity has also been reported, even after short duration exposure to normobaric hypoxia [22,23].

We here report that, prolonged stay at extreme altitudes (>4500 m above sea level) for 6 months and 18 months results in a persistent sympathetic dominance when compared to the sea level populations. The large population size of the study provides strength to our findings on the altered autonomic response on shorter (6 months) and prolonged (18 months) stay at high altitude. Since we observed decrease in SpO₂ of acclimatized lowlanders which showed no signs of improvement despite prolonged stay of 18 months, the increased sympathetic tone in the acclimatized lowlanders could therefore be a compensatory mechanism to ensure increased blood circulation to the peripherals under conditions of low oxygen saturation.

In addition to the autonomic changes, the hemoglobin and hematocrit concentration in the follow up groups were also found to increase significantly in comparison with the baseline. The increase in hemoglobin could be an adaptive physiological response to partially restore the arterial oxygen content which is crucial for altitude adaptation and results due to stimulated erythropoiesis [85–90]. The reduced heart rate in the ALL 18 population on prolonged duration of stay in high altitude that was observed during the present study could be due to an inverse relationship of hemoglobin and hematocrit with heart rate.

In the present study we observed an increase in serum LDL, cholesterol/HDL and LDL/HDL concentrations in ALL 18 along with significant reduction in HDL concentration. This is in

| Table 2. Physiological measures of the study groups (n = 104). |
|-------------------------------------------------------------|
| Normal range | Baseline | ALL 6 | ALL 18 |
| SBP (mm Hg) | 110–130 | 120.86±0.58 | 123.18±0.72 | 123.05±0.80 |
| DBP (mm Hg) | 75–85 | 80.02±0.34 | 82.72±0.70 | 81.99±0.83 |
| Pulse Rate (BPM) | 70–80 | 71.76±0.51 | 85.17±1.12* | 80.22±1.20* |
| SpO₂ (%) | 95–98 | 96.44±0.09 | 89.18±0.20* | 91.69±0.35* |
| BMI | 18.50–24.90 | 21.78±0.12 | 21.84±0.14 | 22.02±0.24 |

Values indicated are means ± SEM. P<0.05: * compared with Baseline; † compared with ALL 6.

SBP: systolic blood pressure; DBP: diastolic blood pressure; SpO₂: hemoglobin oxygen saturation; BMI: body mass index.

doi:10.1371/journal.pone.0084274.t002
contradiction to previous reports on lipid profile of healthy human subjects at moderate altitudes (1000–3500 m) which revealed that there was no risk of developing cardiovascular diseases due to dyslipidemia, reduced plasma total cholesterol, reduced LDL-c and increased level of HDL-c at moderate altitude [91–94]. Investigations on the effect of high altitude exposure on plasma lipids in a group of mountaineers showed reduction in LDL-c that was interpreted as an adaptive response to acute hypoxia exposure [95]. The discrepancy in the findings could be due to a higher altitude in which the study was conducted and long duration of stay at high altitude during the present study. Our findings find support from reports on increase of serum cholesterol, triglycerides and reduction of HDL-c at high altitude by Smith et al. (2011) and other researchers [96–98].

Besides increased susceptibility to hyperlipidemia induced cardiovascular diseases our findings also show significant increase in serum homocysteine concentration in the ALL 6 and ALL 18 compared to baseline. Homocysteine concentration in the serum is influenced by genetic, nutritional, physiological and environmental factors [99–101]. Binding of nitric oxide (NO) with vitamin B12 and its precursors resulting in inhibition of methionine synthase activity could be a plausible reason for the increase in homocysteine that was observed in ALL 6 and ALL 18 groups during the present study [102,103]. Our findings find support from previous reports on upregulation of nitric oxide synthase (NOS) and increase in NO following high altitude exposure [104,105]. Our findings are of clinical relevance considering the fact that hyperhomocysteinemia is accepted to be an independent predictor of cardiovascular diseases [106]. Similar studies by Ashraf et al. (2006) have also revealed that high altitude stay could result into hyperhomocysteinemia as a risk factor for arterial and venous thrombosis. However, we observed that hyperhomocystei-

### Table 3. Heart rate variability indices of the study groups (n = 104).

| Overall HRV measures | Baseline | ALL 6 | ALL 18 |
|----------------------|----------|-------|--------|
| Mean RR (s)          | 0.792 ± 0.010 | 0.671 ± 0.010* | 0.718 ± 0.008** |
| SDNN (s)             | 0.049 ± 0.002 | 0.032 ± 0.001* | 0.042 ± 0.001** |
| RR TI                | 0.123 ± 0.004 | 0.059 ± 0.003* | 0.087 ± 0.001** |
| TINN (ms)            | 351.63 ± 15.92 | 202.58 ± 8.14* | 292.76 ± 6** |
| TP ms²               | 1566.58 ± 94.60 | 748.42 ± 43.62* | 996.05 ± 29.13** |

| Sympathetic activity measures | Baseline | ALL 6 | ALL 18 |
|-------------------------------|----------|-------|--------|
| Mean HR (1/min)              | 77.44 ± 0.88 | 90.24 ± 0.98* | 85.65 ± 0.98** |
| LF power ms²                 | 671.68 ± 34.28 | 412.18 ± 23.11* | 530.36 ± 16.81** |
| LF (nu)                       | 59.06 ± 0.98 | 80.12 ± 0.76* | 69.39 ± 1.19** |

| Parasympathetic activity measures | Baseline | ALL 6 | ALL 18 |
|----------------------------------|----------|-------|--------|
| RMM50D (ms)                     | 39.01 ± 2.74 | 21.10 ± 0.89* | 32.24 ± 0.56** |
| NNS50 (count)                   | 106.15 ± 8.72 | 30.12 ± 3.84* | 71.61 ± 2.98** |
| pNNS50 (%)                      | 17.72 ± 1.50 | 5.80 ± 0.44* | 11.15 ± 0.90** |
| SD1 (ms)                        | 34.82 ± 1.95 | 15.70 ± 0.72* | 24.99 ± 0.57** |
| HF power ms²                    | 468.88 ± 36.92 | 185.82 ± 15.74* | 289.12 ± 8.73** |
| HF (nu)                         | 34.51 ± 0.98 | 16.40 ± 0.91* | 24.59 ± 0.66** |

| Sympatho-vagal balance measure | Baseline | ALL 6 | ALL 18 |
|--------------------------------|----------|-------|--------|
| LF/HF                           | 2.21 ± 0.08 | 3.62 ± 0.18* | 3.07 ± 0.11** |
| Respiration rate                | 11.70 ± 0.07 | 13.17 ± 0.10* | 13.22 ± 0.11** |

### Table 4. Hemoglobin, hematocrit, kidney and liver function profiling of the study groups (n = 104).

| Reference range | Baseline | ALL 6 | ALL 18 |
|-----------------|----------|-------|--------|
| Hb (g/dL)       | 13.80–17.20 | 15.28 ± 0.07 | 17.78 ± 0.06* | 18.47 ± 0.11** |
| Hct (%)         | 43–52    | 46.88 ± 0.17 | 53.56 ± 0.22* | 55.34 ± 0.29** |
| BUN (mg/ml)     | 6–20     | 9.22 ± 0.24 | 9.38 ± 0.23 | 9.42 ± 0.25 |
| Creatinine (mg/ml) | 0.90–1.30       | 0.910 ± 0.012 | 0.928 ± 0.014 | 0.930 ± 0.015 |
| ALT (mg/ml)     | 30–65    | 43.12 ± 0.81 | 44.19 ± 1.02 | 43.46 ± 1.39 |
| AST (mg/ml)     | 15–37    | 29.22 ± 0.28 | 29.50 ± 0.40 | 29.90 ± 1.25 |

Values indicated are means ± SEM.
P<0.05: * compared with Baseline; # compared with ALL 6.

References and Notes:
1. Smith et al. (2011)
2. Ashraf et al. (2006)
3. Homocysteine concentration in the serum is influenced by dietary, nutritional, physiological and environmental factors.
4. NO synthase activity could be a plausible reason for the increase in homocysteine that was observed in ALL 6 and ALL 18 groups during the present study.
5. Our findings are of clinical relevance considering the fact that hyperhomocysteinemia is accepted to be an independent predictor of cardiovascular diseases.
6. Similar studies by Ashraf et al. (2006) have also revealed that high altitude stay could result into hyperhomocysteinemia as a risk factor for arterial and venous thrombosis.
7. However, we observed that hyperhomocysteinemia was interpreted as an adaptive response to acute hypoxic exposure.
**Table 5.** Serum coronary risk factor profiling of the study groups (n = 104).

|                      | Reference range | Baseline       | ALL 6          | ALL 18         |
|----------------------|-----------------|----------------|----------------|----------------|
| **Cholesterol (mg/dl)** | <200            | 124.38±0.88    | 139.84±2.30    | 151.52±4.16    |
| **Triglycerides (mg/dl)** | <150            | 81.22±1.80     | 98.54±2.85     | 129.46±7.36    |
| **HDL (mg/dl)**       | 40–60           | 45.87±0.64     | 39.07±0.88     | 35.30±0.44     |
| **LDL (mg/dl)**       | <100            | 78.73±0.85     | 89.30±2.16     | 104.45±2.40    |
| **Cholesterol/HDL**   | 3.30–4.40       | 2.98±0.03      | 3.64±0.07      | 4.47±0.08      |
| **LDL/HDL**           | 0.50–3.0        | 1.92±0.03      | 2.37±0.07      | 3.27±0.08      |
| **VLDL (mg/dl)**      | ≤30             | 15.98±0.42     | 19.12±0.86     | 26.50±1.17     |
| **Homocysteine (μmol/ml)** | 3.70–13.90    | 9.12±0.07      | 17.48±0.09     | 22.97±1.18     |
| **Vitamin B12 (pg/ml)** | 211–911        | 292.82±3.78    | 224.81±3.86    | 213.70±5.37    |
| **Folic Acid (ng/ml)** | >5.38           | 7.92±0.14      | 6.22±0.15      | 5.77±0.19      |

Values indicated are means ± SEM.
P<0.05: * compared with Baseline; # compared with ALL 6.
Hb: hemoglobin; Hct: hematocrit; BUN: blood urea nitrogen; HDL: high density lipoprotein; LDL: low density lipoprotein; VLDL: very low density lipoprotein; ALT: alanine aminotransferase; AST: aspartate aminotransferase.
doi:10.1371/journal.pone.0084274.t005

**Figure 2.** Graphic representation of serum coronary risk factor profile in baseline and follow up groups. The limits of the boxes represent the middle 50% of the data values; the extent of the lines encompass the interquartile range with extreme outlying data points shown as such. The central line within each box represents the median. **a.** Serum LDL concentration is significantly elevated in ALL 18 (P<0.05) vs Baseline. **b.** Serum cholesterol/HDL ratio is significantly elevated in ALL 18 (P<0.05) vs Baseline. **c.** Serum LDL/HDL ratio is significantly elevated in ALL 18 (P<0.05) vs Baseline. **d.** Serum homocysteine concentration is significantly elevated in ALL 18 (P<0.05) vs Baseline.
doi:10.1371/journal.pone.0084274.g002
nemia at high altitude was independent of vitamin B₁₂ and folic acid [107]. Previous studies by Tayama et al. (2006) have associated hyperhomocysteinemia to systemic arterial stiffness and greater blood pressure response to stress in hypertensive patients [108]. Increased oxidative stress has been previously demonstrated to play a pathophysiological role in the deleterious endothelial effects of homocysteine by promoting vasoconstriction and impairing acetylcholine mediated endothelium-dependent vasodilatation in resistance vessels [109].

The heart rate is controlled by the balance between sympathetic and parasympathetic nervous system activity, and the reduced parasympathetic activity is thought to be responsible for the elevation in heart rate during acute hypoxia [110]. With several investigators reporting increase in parasympathetic activity [111] while others reporting reduction in parasympathetic response [112] and certain reports showing that parasympathetic activity remains unaffected [113], the role of the parasympathetic activity in acute hypoxia is still a subject of debate. Koller et al. (1988) showed that both increased parasympathetic withdrawal and sympathetic stimulation is responsible for the resting heart rate elevation in healthy subjects exposed to a simulated altitude of 6000 m during acute hypoxic exposure [114]. The plasma catecholamine in particular has been reported to regulate the autonomic function. Prominent change in catecholamine concentration has been observed by several researchers following stay at high altitude. Increase in concentration of norepinephrine and epinephrine has been shown after 3–9 weeks of chronic high altitude exposure [115–117]. We also observed increased concentration of plasma norepinephrine and epinephrine in the ALL 6 population in comparison with the baseline and ALL 18. The increased sympathetic activity in association with reduced HRV in ALL 6 population could therefore be attributed to the increased plasma catecholamine concentration. However, after prolonged high altitude exposure of 18 months, the concentration of plasma catecholamine reduced to baseline level. On the contrary our results showed increased concentration of serum homocysteine and other coronary risk factors in ALL 18 when compared with baseline and ALL 6. Hyperhomocysteinemia is known to be an independent risk factor for systemic arterial stiffness and high blood pressure during stress [100]. Homocysteine could promote vasoconstriction and cause impairment of endothelium-dependent vasodilatation in blood vessels [109]. In the presence of normal catecholamine concentration, the reduced HRV after prolonged high altitude exposure for 18 months could be attributed to the increased concentration of serum coronary risk factors and elevated homocysteine. This hypothesis finds support from findings by Acampa et al., 2011 showing that hyperhomocysteineemia is associated with an alteration in the electrical atrial conduction, possibly contributing, at least in part, to the increased risk of cardiac arrhythmias in the denervated hearts of orthotopic

![Figure 3. Concentration of a. Serum ACE (ng/ml) and b. Serum angiotensin II (pg/ml) in baseline and follow ups. doi:10.1371/journal.pone.0084274.g003](image)

![Figure 4. Plasma norepinephrine and epinephrine concentration (pg/ml) in baseline and follow ups. Plasma norepinephrine and epinephrine concentration are significantly elevated in ALL 6 vs Baseline and ALL 18. P<0.05: * compared with Baseline; # compared with ALL 18. doi:10.1371/journal.pone.0084274.g004](image)
heart transplantation (OHT) patients [118]. However, in light of previous findings on negligible role of homocysteine in influencing sympathetic activity [119], further research is required to understand the factors that mediate sympathetic dominance on prolonged stay for >18 months at high altitude.

Conclusion

Based on the findings of the present study, it may be interpreted that the autonomic response is greatly affected following high altitude exposure both for shorter (6 months) as well as prolonged (18 months) durations. However, the autonomic response appears to be regulated by two distinct mechanisms in the ALL 6 and ALL 18. While the autonomic alteration in the ALL 6 group is an outcome of increased sympathetic activity resulting from the increased plasma catecholamine concentration, the alteration of autonomic response in ALL 18 group could be associated with increased concentration of serum coronary risk factors and elevated homocysteine. These findings may also have important clinical implications in assessment of susceptibility to cardiovascular risks in acclimatized lowlanders staying for longer durations at high altitude.

Acknowledgments

The authors thank Dr Paramjit Singh & Col P R Venkatesh for providing support in recruitment of the volunteers as well as logistics during the study. The authors also thank all the volunteers for their cheerful cooperation during the experiments.

Author Contributions

Conceived and designed the experiments: SBS SKH PD VKS KBH RHS. Performed the experiments: PD VKS SKD KBH SKH. Analyzed the data: PD VKS SKH. Contributed reagents/materials/analysis tools: PD VKS SKD KBH. Wrote the paper: PD SKH KBH. Concise review of manuscript and provide the facilities: SBS RHS.

References

1. Malpas SC (2010) Sympathetic nervous system overactivity and its role in the development of cardiovascular disease. Physiol Rev 90: 513–557.
2. Guyton AC, Hall JE (2000) Textbook of Medical Physiology. 10th ed. Philadelphia: WB Saunders Company.
3. Auestad BE, Sepp B, Beckers F (2003) Heart rate variability in athletes. Sports Med 33: 889–919.
4. Rajendra Acharya U, Paul Joseph K, Kannathal N, Lim CM, Suri JS (2009) Chaotic signatures of heart rate variability and its power spectrum in health, aging and heart failure. PLoS One 4(2): e4323.
5. Ramírez-Villalobos JA, Lam-Espinosa E, Ramírez-Moreno DF, Calvo-Echeverry PC, Agredo-Rodriguez W (2011) Heart rate variability dynamics for the prognosis of cardiac risk. PLoS One 6(2): e17060.
6. Wu GQ, Arzno NM, Shen L, Tang DK, Zheng DA, et al. (2009) Augmented sympathetic and parasympathetic indicators of heart rate variability in congestive heart failure. J Am Coll Cardiol 53: 22–30.
7. Kemp AH, Quintana DS, Felmingham KL, Matthews S, Jelinek HF (2012) Depression, comorbid anxiety disorders, and heart rate variability in physically healthy, unmedicated patients: implications for cardiovascular risk. PLoS One 7(2): e30777.
8. Vigo DE, Pérez Lloret S, Viñuela AJ, Pérez Ghita D, Hunicken HM, et al. (2010) Heart rate nonlinear dynamics during sudden hypoxia at 8250 m simulated altitude. Wilderness Environ Med 21: 4–10.
9. Cornélis J, Mollard P, Brugniaux JV, Robach P, Richalet JP (2004) Autonomic control of the cardiovascular system during acclimatization to high altitude: effects of sealdean. J Appl Physiol 97: 935–940.
10. Duplain H, Vollweider L, Delabays A, Nicod P, Bartsch P, et al. (1999) Augmented sympathetic activation during short-term hypoxia and high-altitude exposure in subjects susceptible to high-altitude pulmonary edema. Circulation 99: 1715–1718.
11. Kanai M, Nishihara F, Shimada H, Saito S (2001) Alterations in autonomic nervous control of heart rate among tourists at 2,700 and 3,700 m above sea level. Wilderness Environ Med 12: 8–12.
12. Lanfranchi PA, Colombo R, Cremona G, Baderna P, Spagnolatti L, et al. (2005) Autonomic cardiovascular regulation in subjects with acute mountain sickness. Am J Physiol Heart Circ Physiol 289: 2364–2372.
13. Lanfranchi PA, Colombo R, Cremona G, Baderna P, Spagnolatti L, et al. (2005) Autonomic cardiovascular regulation in subjects with acute mountain sickness. Am J Physiol Heart Circ Physiol 289: 2364–2372.
14. Chen YC, Lin FC, Shiao GM, Chang SC (2000) Effect of rapid ascent to high altitude on autonomic cardiovascular modulation. Am J Med Sci 320: 248–253.
15. Bernardi L (2007) Heart rate and cardiovascular variability at high altitude. Conf Proc IEEE Eng Med Biol Soc 6679–6680.
16. Bernardi L, Pasinou C, Spadaccini G, Calciati A, Robergs R, et al. (1998) Cardiovascular autonomic modulation and activity of carotid baroreceptors at altitude. Clin Sci (Lond) 95: 565–573.
17. Pasinou C, Bernardi L, Spadaccini G, Robergs R, et al. (1996) Autonomic regulation of heart rate and peripheral circulation: comparison of high altitude and sea level residents. Clin Sci (Lond) 90: 81–83.
18. Povea C, Schmidt L, Brugniaux J, Nicot J, Richalet JP, et al. (2005) Effects of intermittent hypoxia on heart rate variability during rest and exercise. High Alt Med Biol 6: 215–225.
19. Prinetti R, Miletó S, Biancardi L, Veicsteinas A (1996) Effects of high altitude acclimatization on heart rate variability in resting humans. Eur J Appl Physiol Occup Physiol 73: 521–528.
20. Hughson RL, Yamamoto Y, McCullough RE, Sutton JR, Reeves JF (1994) Sympathetic and parasympathetic indicators of heart rate control at altitude studied by spectral analysis. J Appl Physiol 77: 2537–2542.
21. Hansen J, Sander M (2003) Sympathetic neural overactivity in healthy humans after prolonged exposure to hypobaric hypoxia. J Physiol 546: 921–929.
22. Xie A, Skatrud JB, Paleos DS, Morgan BJ (2001) Exposure to hypoxia produces long-lasting sympathetic activation in humans. J Appl Physiol 91: 1555–1562.
23. Lusina SJ, Kennedy PM, Inglis JT, McKenzie DC, Aya NT, et al. (2006) Long-term intermittent hypoxia increases sympathetic activity and chemosensitivity during acute hypoxia in humans. J Physiol 573: 961–970.
24. Prabhakaran P, Tripathi KK (2011) Autonomic modulations during 5 hours at 4574 m (15,000 ft) breathing 40% oxygen. Aviat Space Environ Med 82: 483–487.
25. Dumont M, Lysákowski C, Traémier MR, Kayser B (2005) Controversies in altitude medicine. Travel Med Infect Dis 3: 183–188.
26. Kazory A (2010) Emergence of blood urea nitrogen as a biomarker of neurohormonal activation in heart failure. Am J Cardiol 106: 694–700.
27. Moller S, Iversen JS, King A, Bø K, Kjær A, et al. (2010) Reduced baroreflex sensitivity and pulmonary dysfunction in alcoholic cirrhosis: effect of hypothermia. Am J Physiol Gastrointest Liver Physiol 299: 784–790.
28. Baker F, Picton D, Blackwood S, Hunt J, Erdine M (2002) Blinded comparison of folic acid and placebo in patients with ischaemic heart disease: an outcome trial. Circulation 106: 741–747.
29. Albert CM, Cook NR, Gaziano JM, Zaharris E, MacFadyen J, et al. (2008) Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized controlled trial. JAMA 299: 2027–2037.
30. Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, et al. (1998) Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 55: 1449–1455.
31. Guasti L, Petrosuzi MRI, Mainardi LT, Grimaldi P, Zanotta D, et al. (2001) Autonomic function and baroreflex sensitivity during angiotensin-converting enzyme inhibition or angiotensin II AT-1 receptor blockade in essential hypertensive patients. Acta Cardiol 56: 289–295.
32. Fordlund I, Bjornkander I, Ericson M, Held C, Kahan T, et al. (2002) Prognostic implications of autonomic function assessed by analyses of catecholamines and heart rate variability in stable angina pectoris. Heart 87: 415–422.
33. World Health Organization, Switzerland (2008) WHO STEPS. Surveillance. Available: www.who.int/chp/step/ Accessed 12 August 2008.
34. Beck AT, Ward CH, Mendelson M, Mock J, Erbbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry 1: 561–567.
35. Roach RC, Bartsch P, Ode O, Hackett PH, Lake Louise AMS Scoring Committee. (1992) The Lake Louise acute mountain sickness scoring system. In: Sutton JR, Houston CS, Coates G, editors. Hypoxia and Molecular Biology: Burlington: Queen City Press. pp. 272–274.
36. Niskanen JP, Tarvainen PM, Ranta-Aho PO, Karjalainen PA (2004) Software for advanced HRV analysis. Comput Methods Programs Biomed 76: 73–91.
37. Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC (1978) Enzymatic determination of total serum cholesterol. Clin Chem 24: 470–475.
38. Werner M, Gabrielson DG, Eastman G (1981) Ultra micro detection of serum cholesterol. Clin Chem 27: 1048–1051.
39. Chernoff PS, Ross JW (1995) For the National Cholesterol Education Program Working Group on Lipoprotein measurement. National Cholesterol Education Program recommendations for measurement of low-density lipoprotein cholesterol. Executive summary. Clin Chem 41: 1414–1420.
Syed VS, Sharma S, Singh RP (2010) Determinants of acclimatisation in high altitude.
Medical Journal Armed Forces India 66: 261–265.

Vrarrier D, Greenberg MI (2011) Occupational health of miners at altitude: adverse health effects, toxic exposures, pre-placement screening, acclimatization, and worker surveillance. Clin Toxicol (Phila) 49: 629-640.

Rhodes HL, Chesterman K, Chan CW, Collins P, Kesey E, et al. (2011) Systemic blood pressure, arterial stiffness and pulse wave form analysis at altitude. J R Army Med Corps 157: 110–113.

Vauderlei LG, Pastre CM, Hoshi RA, Carvalho TD, Godoy MF (2009) Basic notions of heart rate variability and its clinical applicability. Rev Bras Cir Cardiovasc 24: 305–317.

Farinelli CC, Kayser B, Binzoni T, Cerrettelli P, Girardier L (1994) Autonomic nervous control of heart rate at altitude (5050 m). Eur J Appl Physiol Occup Physiol 69: 502–507.

Ponchial A, Novventa D, Bertaglia M, Carretta R, Zaccaria M, et al. (1994) Cardiovascular neural regulation during and after prolonged high altitude exposure. Eur Heart J 15: 1463–1469.

Zuzewicz K, Bieram B, Kempa G, Kwaerkie K (1999) Heart rate variability in exposure to high altitude hypoxia of short duration. Int J Occup Saf Ergon 5: 337–346.

Liu X, Lu LL, Zhong CF, Cheng ZH, Yuan Q, et al. (2001) Analysis of heart rate variability during acute exposure to hypoxia. Space Med Eng (Eng) 14: 328–331.

Roche F, Reynaud C, Garet V, Pichot V, Costes F, et al. (2002) Cardiac baroreflex control in humans during and immediately after brief exposure to simulated high altitude. Clin Physiol Funct Imaging 22: 301–306.

Schloercheber W, Schrauf R, Lochner M, Von Duvillard SP, Hirttmg H, et al. (2003) Austrian Moderate Altitude Study 2000 (AMAS 2000). The effects of moderate altitude (1,700 m) on cardiovascular and metabolic variables in patients with metabolic syndrome. Eur J Appl Physiol 85: 586–597.

Leong M, Qin J, Huang L, Lu Y, Wu S, et al. (2006) Comparison of heart rate variability in healthy young men during exposure to different altitudes. Sheng Wu Yi Xue Gong Xue Zai Zhi 23: 1195–1197.

Guger C, Krauerst S, Domej V, Edlinger G, Tannerhein M (2008) EEG, EOG and oxygen concentration changes from sea level to a simulated altitude of 4000 m and back to sea level. Neurosci Lett 442: 123-127.

Huang HH, Tseng CY, Fan JS, Yen DH, Kao WF, et al. (2010) Alternations of heart rate variability at lower altitude in the predication of trekkers with acute mountain sickness at high altitude. Clin J Sport Med 20: 58–63.

Malhotra MS, Selvamurthy W, Parayk basa SS, Mukherjee AK, Mathew L, et al. (1976) Responses of the autonomic nervous system during acclimatization to high altitude in man. Aviat Space Environ Med 47: 1076–1079.

Beattie CM (2000) Oxygen concentration changes during childhood and decreases during adulthood among high altitude native Tibetians residing at 3,800–4,200 m. High Alt Med Biol 1: 25–32.

Ward MF, Mil I dge JS, West JB (2000) High Altitude Medicine and Physiology. London: Oxford University Press.

Beattie CM (2001) Adaptations to altitude: A current assessment. Anna Rev Anotropical 30: 423–456.

Pugh LG (1964) Man at high altitude: studies carried out in the Himalaya. Sci Basis Med Annu Rev 32: 54.

Zubieta-Calleja GR, Paulev PE, Zubieta-Calleja L, Zubieta-Castillo G (2007) Altitude adaptation through hemocrit changes. J Pharmacol Pharmacol 58: 811–818.

Tannerhein M, Fusch C, Biont D, Thomas A, Engelhardt M, et al. (2010) Changes of hematocrit and hemoglobin concentration in the cold Himalayan environment in dependence on total body fluid. Sleep Breath 14: 139–139.

Kim GJ, Hannon JP (1968) Effects of high altitude on lipid components of human serum. Proc Soc Exp Biol Med 129: 646–649.

de Mendonça S, Nucet H, Ineichen E, Salazar E, Zerp A, et al. (1979) Lipids and lipoproteins in subjects at 1,000 and 3,500 meter altitude. Arch Environ Health 34: 308–311.

Gargaya, Thakur S, Kapoor D (1999) Lipid profile in chronic renal failure at a moderate altitude of 2250 m. Indian J Med Sci 53: 471–474.

Domínguez Coello S, Cabrera De León A, Bosa Ojeda F, Pérez Méndez LL, Diaz González L, et al. (2000) High density lipoprotein cholesterol increases with living altitude. Int J Epidemiol 29: 63–70.

Férreza J, Ricahejt JP, Coste T, Rachatt C (1988) Changes in plasma lipids and lipoprotein cholesterol during a high altitude mountaineering expedition (8000 m). Eur J Appl Physiol Occup Physiol 57: 749–745.

Smith JD, Giacone K, Marin J, Poirier P, Broderick TL, et al. (2011) Plasma adipokine and hormone changes in mountaineers on ascent to 5300 meters. Wilderness Environ Med 22: 107–114.

Lohuis A (1969) Hypertriglyceridemia in rats at simulated high altitudes. Experience 25: 249–249.

Temt J (1996) Elevation of serum cholesterol at high altitude and its relationship to hemocrit. Wilderness Medicine 7: 216–224.

Ueland PM, Refsum H (1989) Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J Lab Clin Med 114: 473–501.

Ueland PM, Refsum H, Stabler SP, Malinow MR, Anderson A, et al. (1993) Total homocysteine in plasma or serum. Methods and clinical applications. Clin Chem 39: 1764–1771.

Stangen O, Weger M (2003) Interactions of homocysteine, nitric oxide, folate and radicals in the progressively damaged endothelium. Clin Chem Lab Med 41: 1444–1457.
102. Wu JT (2007) Circulating homocysteine is an inflammation marker and a risk factor of life-threatening inflammatory diseases. J Biomed Lab Sci 19: 107–111.

103. Sharma VS, Pilz RB, Ross GR, Magde D (2003) Reactions of nitric oxide with vitamin B12 and its precursor, cobinamide. Biochemistry 42: 8900–8908.

104. Beall CM, Laskowski D, Erzurum SC (2012) Nitric oxide in adaptation to altitude. Free Radic Biol Med 52: 1123–1134.

105. Fagan KA, Morrissey B, Fouty BW, Sato K, Harral JW, et al. (2001) Upregulation of nitric oxide synthase in mice with severe hypoxia-induced pulmonary hypertension. Respir Res 2: 306–315.

106. Strain JJ, Dowey L, Ward M, Pentieva K, McNulty H (2004) B-vitamins, homocysteine metabolism and CVD. P Nutr Soc 63: 597–603.

107. Beall CM, Laskowski D, Erzurum SC (2012) Nitric oxide in adaptation to altitude. Free Radic Biol Med 52: 1123–1134.

108. Ashraf HM, Javed A, Ashraf S (2006) Pulmonary embolism at high altitude and hyperhomocysteinemia. J Coll Physicians Surg Pak 16: 71–73.

109. Hartley LH, Vogel JA, Cruz JC (1974) Reduction of maximal exercise heart rate at altitude and its reversal with atropine. J Appl Physiol 36: 362–365.

110. Richalet JP, Vignon P, Rathat G, Keromes A, Sahutier G, et al. (1985) Catecholamines and histamines at exercise in acute hypoxia (3823 and 4350 m). Effects of atropine. 4th Hypoxia Symposium, Lake Louise, Canada. Burlington, VT: Queen City Printers Inc., USA.

111. Koller EA, Drechsel S, Heus T, Macherel P, Boutellier U (1988) Effects of atropine and propranolol on the respiratory, circulatory, and ECG responses to high altitude in man. Eur J Appl Physiol 57: 163–172.

112. Acampa M, Lazzerini PE, Guidoni F, Rechichi S, Capeschi PL, et al. (2011) Homocysteine and P wave dispersion in patients with heart transplantation. Clin Transplant 25: 119–125.

113. Muntzel MS, Joseph T, Onwumere O (2006) Acute homocysteine administration does not elevate sympathetic nerve activity in rats. Atherosclerosis 184: 290–294.

114. Kalter JA (2003) Chronic hypoxia increases blood pressure and noradrenaline spillover in healthy humans. J Physiol 551: 579–586.